降钙素缓释剂髓腔内植入对大鼠骨质疏松的影响
|
摘要
目的探讨降钙素缓释剂髓腔内植入对大鼠全身骨质疏松的影响。方法将40只3月龄的雌性SD大鼠随机分为4组,A组为卵巢切除联合低剂量降钙素组,B组为卵巢切除联合高剂量降钙素组,C组为卵巢切除联合空白磷酸钙载体组,D组为假手术组,每组各10只,比较植入术后2、4、8周各组血钙和全身骨密度变化。结果植入术后8周,与C组相比,A组和B组股骨近端骨密度均有显著改善(P<0.05),A组和B组血钙浓度较C组显著下降(P<0.05)。结论降钙素缓释剂髓腔内植入可在大鼠体内稳定有效地释放降钙素,降低血钙,提高骨密度。
Objective To evaluate the effect of intramedullary implantation of sustained-release salmon calcitonin on systemic osteoporosis of rats.Methods A total of 40 female SD rats aged 3 months were randomly divided into four groups:ovariectomized rats treated with low dose of calcitonin(Group A),ovariectomized rats treated with high dose of calcitonin(Group B),ovariectomized rats treated only with calcium phosphate carrier(Group C),and sham operation(Group D),with10 rats in each group.Bone mineral density and serum calcium concentration were compared among the 4 groups at 2,4,and 8 weeks after the operation.Results At 8 weeks after the operation,compared with Group C,the bone density at the proximal femur was improved significantly(P<0.05)and the level of serum calcium was reduced significantly in Group A and Group B(P<0.05).Conclusion Intramedullary implantation of sustained-release salmon calcitonin can release the calcitonin in rats in an effective and stable manner to improve bone density and reduce serum calcium.
Objective To evaluate the effect of intramedullary implantation of sustained-release salmon calcitonin on systemic osteoporosis of rats.Methods A total of 40 female SD rats aged 3 months were randomly divided into four groups:ovariectomized rats treated with low dose of calcitonin(Group A),ovariectomized rats treated with high dose of calcitonin(Group B),ovariectomized rats treated only with calcium phosphate carrier(Group C),and sham operation(Group D),with10 rats in each group.Bone mineral density and serum calcium concentration were compared among the 4 groups at 2,4,and 8 weeks after the operation.Results At 8 weeks after the operation,compared with Group C,the bone density at the proximal femur was improved significantly(P<0.05)and the level of serum calcium was reduced significantly in Group A and Group B(P<0.05).Conclusion Intramedullary implantation of sustained-release salmon calcitonin can release the calcitonin in rats in an effective and stable manner to improve bone density and reduce serum calcium.
引文
[1]郭世拔,罗先正,邱贵兴.骨质疏松基础与临床[M].天津:科学技术出版社,2001:522-531.
[2]Espanol M,Perez RA,Montufar EB,et al.Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications[J].Acta Biomater,2009,5(7):2752-2762.
[3]Low KL,Tan SH,Zein SH,et al.Calcium phosphate-based composites as injectable bone substitute materials[J].J Biomed Mater Res B Appl Biomater,2010,94(1):273-286.
[4]Victor SP,Sharma CP.Calcium phosphates as drug delivery systems[J].J Biomater Tiss Eng,2012,2(4):269-279.
[5]Park J,Lee G,Shin US.Self-hardening microspheres of calcium phosphate cement with collagen for drug delivery and tissue engineering in bone repair[J].J Am Cera Soc,2011,94(9):3149.
[6]陈柏龄,廖威明,李佛保,等.轻度承重活动对卵巢切除大鼠骨密度组织计量和生物力学的影响[J].中山大学学报(医学科学版),2001,22(3):187-191.
[7]Curtis JR,Safford MM.Management of osteoporosis among the elderly with other chronic medical conditions[J].Drugs Aging,2012,29(7):549-564.
[8]Lee HJ,Kim SY,Kim GS,et al.Fracture,bone mineral density,and the effects of calcitonin receptor gene in postmenopausal Koreans[J].Osteoporos Int,2010,21(8):1351-1360.
[9]Ezzat BA.Validity of prevention of glucocorticoid-induced alveolar bone loss in rat by either calcitonin or alendronate administration[J].Arch Oral Biol,2010,55(10):788-796.
[10]Andresen CJ,Moalli M,Turner CH,et al.Bone parameters are improved with intermittent dosing of vitamin D3 and calcitonin[J].Calcif Tissue Int,2008,83(6):393-403.
[11]Lewiecki EM.Emerging drugs for postmenopausal osteoporosis[J].Expert Opin Emerg Drugs,2009,14(1):129-144.
[12]Tang Y,Singh J.Thermosensitive drug delivery system of salmon calcitonin:in vitro release,in vivo absorption,bioactivity and therapeutic efficacies[J].Pharm Res,2010,27(2):272-284.
[13]Binkley N,Bolognese M,Sidorowicz-Bialynicka A,et al.A phase 3 trial of the efficacy and safety of oral recombinant calcitonin:the oral calcitonin in postmeno-pausal osteoporosis(ORACAL)trial[J].J Bone Miner Res,2012,27(8):1821-1829.
[14]Maricic MJ.Oral calcitonin[J].Curr Osteoporos Rep,2012,10(1):80-85.
[2]Espanol M,Perez RA,Montufar EB,et al.Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications[J].Acta Biomater,2009,5(7):2752-2762.
[3]Low KL,Tan SH,Zein SH,et al.Calcium phosphate-based composites as injectable bone substitute materials[J].J Biomed Mater Res B Appl Biomater,2010,94(1):273-286.
[4]Victor SP,Sharma CP.Calcium phosphates as drug delivery systems[J].J Biomater Tiss Eng,2012,2(4):269-279.
[5]Park J,Lee G,Shin US.Self-hardening microspheres of calcium phosphate cement with collagen for drug delivery and tissue engineering in bone repair[J].J Am Cera Soc,2011,94(9):3149.
[6]陈柏龄,廖威明,李佛保,等.轻度承重活动对卵巢切除大鼠骨密度组织计量和生物力学的影响[J].中山大学学报(医学科学版),2001,22(3):187-191.
[7]Curtis JR,Safford MM.Management of osteoporosis among the elderly with other chronic medical conditions[J].Drugs Aging,2012,29(7):549-564.
[8]Lee HJ,Kim SY,Kim GS,et al.Fracture,bone mineral density,and the effects of calcitonin receptor gene in postmenopausal Koreans[J].Osteoporos Int,2010,21(8):1351-1360.
[9]Ezzat BA.Validity of prevention of glucocorticoid-induced alveolar bone loss in rat by either calcitonin or alendronate administration[J].Arch Oral Biol,2010,55(10):788-796.
[10]Andresen CJ,Moalli M,Turner CH,et al.Bone parameters are improved with intermittent dosing of vitamin D3 and calcitonin[J].Calcif Tissue Int,2008,83(6):393-403.
[11]Lewiecki EM.Emerging drugs for postmenopausal osteoporosis[J].Expert Opin Emerg Drugs,2009,14(1):129-144.
[12]Tang Y,Singh J.Thermosensitive drug delivery system of salmon calcitonin:in vitro release,in vivo absorption,bioactivity and therapeutic efficacies[J].Pharm Res,2010,27(2):272-284.
[13]Binkley N,Bolognese M,Sidorowicz-Bialynicka A,et al.A phase 3 trial of the efficacy and safety of oral recombinant calcitonin:the oral calcitonin in postmeno-pausal osteoporosis(ORACAL)trial[J].J Bone Miner Res,2012,27(8):1821-1829.
[14]Maricic MJ.Oral calcitonin[J].Curr Osteoporos Rep,2012,10(1):80-85.